Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy
Francisco del Caño‐Ochoa(Instituto de Salud Carlos III), Santiago Ramón‐Maiques(Instituto de Biomedicina de Valencia), Hema Patel(Children's Hospital of Wisconsin), Mehran Beiraghi Toosi(Mashhad University of Medical Sciences), Bobby G. Ng(Sanford Burnham Prebys Medical Discovery Institute), Mohammed Almannai(King Fahd Medical City), Orly Elpeleg(Hadassah Medical Center), Ronald D. Cohn(University of Toronto), M. Chiara Manzini(Rutgers, The State University of New Jersey), Gregory Costain(University of Toronto), Ali Al‐Otaibi(King Fahd Medical City), Jill A. Rosenfeld(Baylor College of Medicine), V. Reid Sutton(Baylor College of Medicine), Ehsan Ghayoor Karimiani(St George's, University of London), Malak Abedalthagafi(Tufts University), Lynne A. Wolfe(National Institutes of Health), Henry Houlden(University College London), Reza Maroofian(National Hospital for Neurology and Neurosurgery), Michael Muriello(Johns Hopkins University), Edvardson Shimon(Hadassah Medical Center), Pengfei Liu(Macau University of Science and Technology), Hudson H. Freeze(Sanford Burnham Prebys Medical Discovery Institute)
Cited by 27
Related Papers
Genome-wide association study reveals genetic risk underlying Parkinson's disease
|Nature Genetics|2009|2k
Symbol Nomenclature for Graphical Representations of Glycans
|Glycobiology|2015|1.1k
Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation
|New England Journal of Medicine|2016|774
Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy
|Nature Genetics|2001|618